Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): a Retrospective and Prospective Observational Study
Overview
Authors
Affiliations
Objectives: The severity of liver disease in the hepatitis C virus (HCV)-infected population in the United States remains uncertain. We estimated the prevalence of cirrhosis in adults with chronic hepatitis C (CHC) using multiple parameters including liver biopsy, diagnosis/procedure codes, and a biomarker.
Methods: Patients enrolled in the Chronic Hepatitis Cohort Study (CHeCS) who received health services during 2006-2010 were included. Cirrhosis was identified through liver biopsy reports, diagnosis/procedure codes for cirrhosis or hepatic decompensation, and Fibrosis-4 (FIB-4) scores ≥5.88. Demographic and clinical characteristics associated with cirrhosis were identified through multivariable logistic modeling.
Results: Among 9,783 patients, 2,788 (28.5%) were cirrhotic by at least one method. Biopsy identified cirrhosis in only 661 (7%) patients, whereas FIB-4 scores and diagnosis/procedure codes for cirrhosis and hepatic decompensation identified cirrhosis in 2,194 (22%), 557 (6%), and 482 (5%) patients, respectively. Among 661 patients with biopsy-confirmed cirrhosis, only 356 (54%) had an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for cirrhosis. Older age, male gender, Asian race, Hispanic ethnicity, genotype 3 infection, HIV coinfection, diabetes, history of antiviral therapy, and history of alcohol abuse were independently associated with higher odds of cirrhosis (all, P<0.05). Conversely, private health insurance coverage, black race, and HCV genotype 2 were associated with lower odds of cirrhosis.
Conclusions: A high proportion of patients with biopsy-confirmed cirrhosis are not assigned ICD-9 codes for cirrhosis. Consequently, ICD-9 codes may not be reliable as the sole indicator of the prevalence of cirrhosis in cohort studies. Use of additional parameters suggests a fourfold higher prevalence of cirrhosis than is revealed by biopsy alone. These findings suggest that cirrhosis in CHC patients may be significantly underdocumented and underdiagnosed.
Miller-Archie S, Walters S, Bocour A, Moore M, Wiewel E, Singh T J Infect Dis. 2022; 226(Suppl 3):S363-S371.
PMID: 36208165 PMC: 9547527. DOI: 10.1093/infdis/jiac292.
Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant.
Wayda B, Sandhu A, Parizo J, Teuteberg J, Khush K J Heart Lung Transplant. 2021; 41(1):37-47.
PMID: 34635381 PMC: 8973316. DOI: 10.1016/j.healun.2021.09.002.
Khatana S, Hanff T, Nathan A, Dayoub E, Grandin E, Rame J Circ Heart Fail. 2021; 14(5):e008277.
PMID: 33993721 PMC: 8153026. DOI: 10.1161/CIRCHEARTFAILURE.120.008277.
Quaranta M, Ferrigno L, Monti M, Filomia R, Biliotti E, Iannone A Hepatol Int. 2020; 14(3):362-372.
PMID: 32279177 PMC: 7220859. DOI: 10.1007/s12072-020-10034-0.
Abara W, Spradling P, Zhong Y, Moorman A, Teshale E, Rupp L J Gastrointest Cancer. 2019; 51(2):461-468.
PMID: 31124041 PMC: 6874701. DOI: 10.1007/s12029-019-00255-4.